A small-molecule mitochondrial protonophore (uncoupler) studied preclinically for obesity and metabolic disease; not a peptide and not approved for human use.
BAM15 is a small molecule (not a peptide) that acts as a mitochondrial "uncoupler." Mitochondria normally build up a proton gradient across their inner membrane and then harvest that gradient to make ATP, the cell's energy currency. An uncoupler lets protons leak back across the membrane without making ATP, so the energy is released as heat instead — effectively making the cell burn more fuel.
The interest in BAM15 is metabolic: by increasing energy expenditure, uncouplers can, in animal models, reduce body fat and improve markers of metabolic health without requiring reduced food intake. BAM15 was specifically pursued because it was reported to act on mitochondria while having a wider safety margin in preclinical studies than older, dangerous uncouplers such as DNP (2,4-dinitrophenol).
The evidence base is preclinical. BAM15's reported metabolic benefits come from cell and rodent studies; it is not an approved medicine and human clinical safety and efficacy are not established. Because uncoupling raises energy expenditure and heat production, the entire chemical class carries an inherent and potentially serious risk if dosing is excessive.
Searching the published record…
Searching the published record…
Searching the published record…
Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.